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A B S T R A C T
Purpose: To determine the inﬂuence of epilepsy and its treatment on pregnancy and its outcome.
Design: Controlled, observational study.
Setting: National Health Service maternity hospitals in Liverpool and Manchester regions.
Population: 277 women with epilepsy (WWE) and 315 control women.
Methods: WWEwere recruited from antenatal clinics. Controls were matched for age and parity but not
gestational age. Information was obtained by interview and from clinical records.
Main outcome measures: Obstetric complications, mode of delivery, condition of newborn.
Results: Distribution of epilepsy syndromes was similar to previous surveys. Most WWE (67%) received
monotherapy with carbamazepine, sodium valproate or lamotrigine. Half WWE had no seizures during
pregnancy but 34% had tonic clonic seizures. Seizure-related injuries were infrequent. Pregnancies with
obstetric complications were increased in women with treated epilepsy (WWTE 45%, controls 33%;
p = 0.01). Most had normal vaginal delivery (WWTE 63%, controls 61%; p = 0.65). Low birth weight was
not increased (WWTE 6.2%, controls 5.2%; p = 0.69). There were more major congenital malformations
(MCM) (WWTE 6.6%, controls 2.1%; p = 0.02) and fetal/infant deaths (WWTE 2.2%, controls 0.3%;
p = 0.09). Amongst monotherapies MCM prevalence was highest with valproate (11.3%; p = 0.005).
Lamotrigine (5.4%; p = 0.23) and carbamazepine (3.0%; p = 0.65) were closer to controls (2.1%). Therewas
no association between MCM and dose of folic acid pre-conception.
Conclusion: MCM were more prevalent in the babies of WWTE particularly amongst those receiving
sodium valproate.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Women with epilepsy (WWE), who are considering pregnancy,
may have concerns about worsening of seizures, obstetric
complications, abnormal delivery and malformations in their
children. Previous research has shown that most WWE experience
no increase in seizures during pregnancy.1–7 Several authors8–11
have found increased prevalence of speciﬁc complications includ-
ing vaginal bleeding, anaemia, vomiting, urinary infection,
hypertension and breech presentation. Others concluded that* Corresponding author at: Department of Genetic Medicine, St Mary’s Hospital,
Central Manchester University Hospitals, Oxford Road, Manchester M13 9WL, UK.
Tel.: +44 161 276 6269; fax: +44 161 276 6145.
E-mail address: gemawer@btinternet.com (G. Mawer).
1 See Appendix A for a complete list of group members.
1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.11.008most WWE have uncomplicated pregnancies.3,4,6 Increased
caesarean section rate,2,8 pre-term delivery and low birth
weight4,9,10 have been reported.
There is a 2–3-fold increase in major congenital malformations
(MCM) in babies of WWE treated with a single antiepileptic drug
(AED) during pregnancy.12 Higher rates have been reported with
sodium valproate.6,13–17 A review18 of several studies found
increased stillbirth and neonatal death in pregnancy with epilepsy
but this was not replicated in two recent studies.2,11 Increased
maternal mortality during and soon after pregnancy is also
recognised.4,19
This paper reports on the pregnancies, deliveries and immedi-
ate outcomes in a study of WWE. Unlike many previous studies it
utilises a control group of women without epilepsy recruited
speciﬁcally for the purpose. The number of women recruited also
allows for important statistical and clinical differences to be
observed.vier Ltd. All rights reserved.
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This was an observational study. The investigators played no
part in clinical management. WWE were recruited from antenatal
clinics at 11 National Health Service (NHS) hospitals within
Merseyside and Greater Manchester between 2000 and 2006.
Midwives in the antenatal clinics approached each woman, who
gave a history of epilepsy, whatever her stage of gestation. An
information sheet was provided with a verbal explanation of the
project. The research nurse then made contact by phone, gave
more detail, posted the consent form and arranged to meet the
WWE as soon as possible. All consenting WWE were followed up
but those with chronic medical conditions predisposing to
abnormality in the child and those with an earlier pregnancy in
the study are not included in this report.
The longer term objective of this 6-year study is to monitor a
cohort of children born to WWE and a corresponding cohort of
children born to mothers without epilepsy. By comparing the
physical and cognitive development of the two groups it is hoped
to assess the impact of in utero exposure to different AED. Using
the Differential Ability Scale as the primary outcome measure and
seeking 80% power at a 95% conﬁdence level to detect a difference
of 1.5 SD, it was estimated that 45 children were required in each
monotherapy group. To allow for fetal deaths and withdrawals the
recruitment target became a minimum of 50 pregnancies in each
monotherapy group.
WWE receiving monotherapy with carbamazepine (CBZ),
lamotrigine (LTG) or valproate (VPA) were also invited to join
an NIH funded, multi-centre study (Neurodevelopmental Effects of
Antiepileptic Drugs; NEAD) which compares outcomes with
different AED. Some results from children of these women have
been published previously.6,20,21 The NEAD study excludes women
on polytherapy and does not incorporate a control group of women
without epilepsy.
Women without epilepsy were recruited from the same
NHS hospital antenatal clinics. The research nurse after
interviewing each WWE searched through the records of healthy
women, who attended the clinic on the same day or a few days
later. The aim was to ﬁnd a woman control, who matched each
WWE for age (within a 5-year band), for parity, for residential
district (postal code) and employment. Since the WWE and the
healthy woman controls were attending the same clinic at about
the same time it was assumed that there would be no systematic
difference in gestational age. This assumption proved to be
incorrect.
Antenatal and obstetric care outside the NHS is rare in the UK
particularly for WWE but even within the NHS, WWE and healthy
women follow different patterns of antenatal care. Both groups
usually present themselves to their General Medical Practitioner
for health care during the pregnancy but thereafter the manage-
ment is different. A pregnantWWE is typically referred directly for
hospital-led antenatal care, whereas a potential ‘control’ woman
with no medical history is typically referred to the community
mid-wife service often based in the local medical practice.
Thus hospital midwives often meet WWE during the ﬁrst
trimester or early in the second, whereas they commonly meet
women without epilepsy ﬁrst at the 19–21-week scan. This
phenomenon has created within this study a systematic difference
betweenWWEandwomen controlswith respect to gestational age
at recruitment.
There was no payment to women for study visits to hospital
beyond expenses for travel and refreshments. Nevertheless, it was
expected that a high proportion of WWE would take part.
Acceptance amongst control women was expected to be about
50%. Research nurses therefore approached two potential control
subjects for each WWE.At her ﬁrst meeting with each newly recruited subject the
research nurse took a personal and medical history in accordance
with the prospectively designed Patient Basic and Control Basic
Record Forms. Questions covered education, occupation, welfare
beneﬁts and lifestyle issues such as use of tobacco and alcohol.
Previous miscarriages and terminations were recorded but the
reasons for termination were not ascertained. The Patient Basic
Forms also covered seizure history and details of the clinical units
and physicians involved in the investigation and treatment of the
epilepsy. An epilepsy specialist (G.M.) conﬁrmed seizure type,
syndrome diagnosis, current seizure frequency and antiepileptic
medication. Information from the patient was supplemented from
clinical records.
The epilepsy syndrome was classiﬁed as symptomatic/
cryptogenic focal (localisation-related) or idiopathic generalised
(IGE). When uncertain whether tonic clonic seizures were
primary or secondarily generalised, the epilepsy was unclassi-
ﬁed. Seizures were recorded as tonic clonic or non-convulsive
(simple/complex partial, myoclonic, absence). Frequency was
ascertained from the patient and an observer, if available, since
not all WWE kept seizure diaries. Seizure-related injuries and
hospital admissions were noted. Seizures after delivery were not
recorded.
Details of each pregnancy were recorded in prospectively
designed Patient and Control Pregnancy & Delivery Record Forms.
These were ﬁlled in partly at a meeting with the research nurse
during later pregnancy, often on the day of an ultrasound scan. The
remainder was ﬁlled in after delivery, if possible before discharge
from the maternity unit. Failing this the information was obtained
by phone. The forms covered AEDmedication, the timing of dosage
changes, nutritional supplements, presence of speciﬁc complica-
tions of pregnancy, investigations, attendance for ultrasound
scans, the delivery and the immediate outcome. The occurrence of
seizures, injuries and emergency admissions were recorded on the
Patient Forms. Obstetric records were studied for details of
complications, reports of ultrasound scans, fetal presentation
and mode of delivery.
Condition at birth (Apgar score, neonatal problems, need for
special care, birth weight) was recorded on the First Paediatric
Assessment Form. Congenital abnormalities were identiﬁed from
reports of fetal scans and paediatric medical examination of the
baby before discharge. Length, occipito-frontal circumference and
details of physical examination were recorded. Some congenital
abnormalities were not identiﬁed until later during follow up,
which is continuing up to 6 years. These have also been included.
Major malformations (MCM) were distinguished from minor
anomalies using Eurocat instructions for the Surveillance of
Congenital Abnormalities.22 MCM in babies with chromosome
abnormalities were not included in the analysis of possible adverse
effects of AED.
The study was conceived and designed as a prospective study.
The content of the Basic Form however related mainly to the
previous medical history and was clearly retrospective. The
content of the Pregnancy & Delivery Form was mixed. The data
on pre-conceptual dosage of AED and folate related to the time
before recruitment and was retrospective. Data on mode of
delivery was prospective. The point of transition between the
recording of past history and of events as they happened depended
on the date of recruitment. Since a substantial proportion of WWE
and most women controls were recruited in the second and third
trimester, the term prospective has not been applied to the early
results of this 6-year long study.
Physical examination and cognitive function assessments of
each child were repeated at 1–2 years, 3 and 6 years. Details of the
examinations, test batteries and Record Forms are beyond the
scope of the present report.
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epilepsy’ (WWTE), who were taking AED to prevent seizures and
(2) those with ‘untreated epilepsy’ (WWUTE), who were taking no
AED. The treated group was expected to have a poorer outcome in
terms of complications and MCM. Its results have been presented
separately to avoid bias towards a good outcome arising from
inclusion of the untreated group thatwas expected to resemble the
control group. A similar approach was adopted by Viinikainen et
al.7
Differences between groups were expressed as odds ratios (OR)
with 95% conﬁdence intervals (CI). Explicit p values were derived
from Chi2 test, or Fisher’s exact test for small samples. Unpaired t-
test was used to compare continuous variables. Mann–Whitney U-
test was used to compare variables not normally distributed.When
repeated tests were applied to related features (obstetric
complications) the effect of a multiple test correction (Bonferroni)
was noted. Discriminant analysis (Wilks lambda) was used to
identify and rank variables that were signiﬁcant discriminators for
MCM. Subject variables were converted to binary form for this
analysis to ensure the samples were from multivariate normal
populations and had equal variance-covariancematrices (Box’sM).
Thus, for example, maternal age was recorded as below or above
the study populationmean, and gestational age at recruitmentwas
recorded as early (up to 20 weeks, before anomaly scan) or late
(more than 20 weeks, after anomaly scan). Because WWE and
women controls were not matched for gestational age, particular
attention has been given to the inﬂuence of this variable. Tests
were accessed through Conﬁdence Interval Analysis for Windows
and SPSS version 16 for Windows. Missing data below 10% was
ignored.
3. Results
WWE (277) were recruited between 7 and 38 weeks gestation
with 169 (61%) in the ﬁrst 20 weeks and 108 (39%) thereafter. The
distribution was uni-modal with the peak frequency of enrolment
between 9 and 16 weeks. Women controls (315) were recruited
between 8 and 39 weeks with 101 (32%) in the ﬁrst 20 weeks and
214 (68%) thereafter. The distribution was bi-modal with one peak
between 19 and 22 weeks and a second between 26 and 33 weeks.
Acceptance rates amongst WWE and control women were
estimated as 80% and 60%, respectively. Three years into the
study 84,872 women had given birth in the participating hospitals
and from that population 231 pregnant WWE had been recruitedTable 1
Clinical features of pregnant women with epilepsy (WWE).
Seizures during pregnancy
None
Non-convulsive only
Tonic clonic (TC)a
Data missing
Total
Antiepileptic drug treatment Epilepsy syndrom
N % Focal
None 46 16.6 17
Monotherapy 185 66.8 92
Carbamazepine 74 26.7 55
Valproate 57 20.6 9
Lamotrigine 40 14.4 17
Other 14 5.1 11
Polytherapy 46 16.6 30
Total 277 100 139
a Women with epilepsy, who had one or more tonic clonic (TC) seizures during the
idiopathic generalised epilepsy, unclass.: unclassiﬁed, wk: weeks, other: gabapentin, o(2.72 per thousand). The number of WWE receiving CBZ
monotherapy was well above the target and subsequent recruit-
ment was narrowed to those receiving VPA or LTG. Three WWE
were excluded from this report because of neuroﬁbromatosis,
tuberous sclerosis and heroin addiction.
One hundred and eight (39%) of the WWE also actively
participated in the NEAD study.6,20,21 The ﬁrst of the NEAD reports
focussed on serious adverse outcomes (MCMand fetal death) in the
offspring of WWTE on monotherapy. Four of the babies with MCM
reported here were described in that report.6 These are identiﬁed
by the footnote ‘c’ in Table 5. No other information from this study
has been published earlier.
WWE (mean 27.4 years) were a little younger than control
women (mean 28.7 years), difference 1.3 (95% CI 0.41–2.25;
p = 0.005). There was no difference in parity between WWE
(0:1:2:3 or more = 143:90:23:22) and controls (174:94:34:13)
(Chi2 5.27, degrees of freedom 3; p = 0.15).
3.1. Epilepsy and AED usage
Half of the WWE had no seizures during their pregnancy. This
proportion remained high (46%) even if WWUTE were excluded.
Fourteen percent had non-convulsive seizures only but a third
experienced tonic clonic seizures (see Table 1). The most frequent
syndrome diagnosis was symptomatic/cryptogenic focal epilepsy.
Amongst those with IGE, 1 in 5 women had juvenile myoclonic
epilepsy.
Thirty-four women attended hospital in seizure-related emer-
gencies. These women were all experiencing tonic clonic seizures.
Most were allowed home after a few hours observation, which
included fetal monitoring. Ten were observed overnight and two
for several days. Four women were observed overnight on 2 or
more occasions. Onewoman needed suture of a headwound. None
were in convulsive status.
Therewere 46WWUTE (17%)who took no AED before or during
pregnancy (see Table 1). Their syndrome diagnoses were focal
(17), idiopathic generalised (15) and unclassiﬁed (14). Twenty-
three had been free from seizures for more than 2 years and 10 for
more than 10 years. Seven continued to experience non-convulsive
seizures (absences 2, simple or complex partial 5). Twelve had a
history of infrequent tonic clonic seizures; of these only one had
such seizures during the pregnancy.
Most WWE (67%) received one AED only. CBZ (range 100–
1600 mg/day; median 600) was prescribed mainly when theWWE %
144 52.0
38 13.7
94 33.9
1 0.4
277 100.0
e WWE with TCa seizures
IGE Unclass. 0–20 wk 21 wk to term
15 14 0 1
66 27 56 42
6 13 20 12
40 8 21 15
17 6 11 12
3 0 4 3
13 3 20 24
94 44 76 67
pregnancy, with or without non-convulsive seizures; N: number of women, IGE:
xazepam, phenytoin, topiramate or vigabatrin.
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median 900) was prescribed mainly for WWEwith IGE. LTG (range
50–800 mg/day; median 200) was prescribed equally for WWE
with either diagnosis.
Polytherapy (two or more AED) was prescribed for 46 WWE
(17%). In 26 this included VPA giving a total of 83WWE prescribed
VPA asmono- or polytherapy. Thirty-nine of thesewere prescribed
1000 mg/day or more.
Ninety-seven WWE (35%) had drug treatment changes during
pregnancy. Forty women on monotherapy had their AED dose
raised; ﬁfteen had their dose lowered and in 14 the AED was
stopped. Fifteen women on polytherapy had treatment increased
and 7 had treatment reduced. Five had one AED substituted for
another and one woman had her three AEDs withdrawn. Most (32/
40) of those inwhommonotherapywas increased had experienced
seizures (23 convulsive) during the pregnancy.
The number of women in the different treatment groups, who
had one or more tonic clonic seizures, is shown in Table 1. In
general fewer women had convulsive seizures during the second
half of pregnancy (21 weeks to term) than in the ﬁrst 20 weeks.
This did not apply to those on LTG or to those on polytherapy.
Before conception a folic acid supplement at high dose (4 or
5 mg/day) was taken by 91 WWE (32.9%). In the remainder the
dose was the standard nutritional daily requirement of 0.4 mg
(9.0%), none (55.6%) or unknown (2.5%).
3.2. Obstetric complications and mode of delivery
Pregnancies with obstetric complications were more frequent
in WWTE but no single complication was increased signiﬁcantly
(see Table 2). WWUTE (30.4%)(14/46) resembled controls
(p = 0.87). The higher frequency of vaginal bleeding in WWTE
(15.7%, controls 9.6%; p = 0.05) was not signiﬁcant after Bonferroni
correction for multiple tests (p value for signiﬁcance 0.01). Most
bleeding (70–80%) occurred in the ﬁrst half of pregnancy. Ante-
partumhaemorrhagewas reported twice inWWTE and in controls.
Vaginal bleeding was most prevalent in the WWTE who
received polytherapy (21.7%, 10/46, controls 9.6%, 30/311;
p = 0.02). The frequencies with VPA (19.3%, 11/57; p = 0.04) and
CBZ (17.6%, 13/74; p = 0.06)were similar. The frequencieswith LTG
(2.5%, 1/39) and other monotherapies (7.1%, 1/14) were low. The
frequency of vaginal bleeding was higher in women recruited later
(after 20 weeks gestation) than in women recruited earlier; thisTable 2
Obstetric complications and mode of delivery in women with treated epilepsy (WWTE
Problem WWTE N=231 Control wome
y n dm y n
Complications
Any 104 126 1 103 2
Vaginal bleeding 36 194 1 30 2
Urinary infection 24 206 1 35 2
Hypertension 20 210 1 21 2
Breech presentation 18 204 9 16 2
Fetal distress 11 211 9 10 2
Multiple pregnancy 5 225 1 1 3
Mode of delivery
Normal 140 83 8c 187 1
Caesarean section 58 165 8 76 2
Vacuum assisted 16 207 8 20 2
Forceps assisted 8 215 8 22 2
Vaginal breech 1 222 8 4 3
y: yes, n: no, dm: data missing, p: probability.
a 0.01 required for signiﬁcance after Bonferroni correction for multiple comparisons
b Fisher’s exact test.
c 8 mode of delivery ‘unknown’ =3 fetal deaths +5 lost to follow up.
d 6 mode of delivery ‘unknown’ =1 fetal death+5 lost to follow up. Data from 2nd tapplied both to WWTE (late 20.0%, early 12.9%; p = 0.19) and to
women controls (late 10.3%, early 8.2%; p = 0.68). In neither case
was the difference signiﬁcant.
There was no signiﬁcant increase in other complications in the
WWTE. Raised maternal alpha-fetoprotein, oligo-/poly-hydram-
nios, cholestasis, gestational diabetes and prolonged rupture of
membranes, were each infrequent (<2%) and not amenable to
conﬁdence interval analysis. Probabilities of differences ranged
from p = 1.00 for poly-hydramnios to p = 0.24 for prolonged
rupture of membranes (Fisher’s exact test).
Most WWTE (62.8%) and controls (60.5%) had normal vaginal
deliveries (see Table 2). Women with untreated epilepsy were
similar (68.9%) (31/45). There were no signiﬁcant differences in
abnormal deliveries between WWTE and controls. Most of the
babies presenting by the breech in each group were delivered by
caesarean section.
3.3. Newborn
Gestational age at birth (range 29–42 weeks: mode 40) was
similar in the babies of WWTE and controls (p = 0.14; Mann–
Whitney U-test) and the difference in mean birth weights was
small (WWTE 3.32 kg, controls 3.42 kg; difference 0.10 kg, 95% CI
(0.001–0.20) p = 0.05). There were no signiﬁcant differences (see
Table 3) in the frequencies of pre-term or low birth weight babies,
those with birth weights at or below the 9th centile, or those
admitted for special care. The babies ofWWUTE did not differ from
controls with respect to gestational age at birth (p = 0.19) or birth
weight (p = 0.72).
3.4. Major malformations and deaths
The prevalence of MCM amongst babies of WWTE (6.6%) was
greater than amongst control babies (2.1%) (see Table 4). The
highest prevalence (16.7%) was in babies exposed to VPA within
polytherapy. This was followed by VPA as monotherapy (11.3%).
When all babies exposed to VPA (as mono- or polytherapy) were
excluded, the MCM amongst those exposed to other AEDs fell to
3.0%, which did not differ from the level in control babies. The
babies of WWUTE (AED none) did not differ from controls.
The prevalence of MCM in offspring exposed to higher doses of
VPA (>1000 mg/day) as monotherapy was 16.0% (4/25) com-
pared with 7.1% (2/28) at doses below 1000 mg/day but the) and control women.
n N=315 Odds ratio Conﬁdence interval p
dm OR 95% CI
08 4 1.67 1.18–2.38 0.01
81 4 1.74 1.04–2.92 0.05a
76 4 0.92 0.53–1.59 0.78
90 4 1.32 0.70–2.49 0.42
93 6 1.62 0.81–3.24 0.21
99 6 1.56 0.65–3.74 0.37
10 4 6.89 0.09b
22 6d 1.10 0.77–1.57 0.65
33 6 1.08 0.73–1.60 0.76
89 6 1.12 0.57–2.21 0.86
87 6 0.49 0.21–1.11 0.09
05 6 0.34 0.41b
.
win excluded.
Table 3
Pre-term deliveries and related features in babies of women with treated epilepsy (WWTE) and babies of women with no history of epilepsy (controls).
Problem WWTE babies Control babies Odds ratio Conﬁdence interval p
y n dm y n dm OR 95% CI
Pre-term delivery (36 wks) 18 194 6 16 289 3 1.68 0.83–3.37 0.15
Low birth weight (2.5 kg) 13 197 8 15 275 18 1.21 0.56–2.60 0.69
Birth weight centile (9th) 14 196 8 15 275 18 1.31 0.65–2.73 0.56
Admitted to SCBU 23 188 7 23 264 21 1.40 0.77–2.58 0.28
Total recorded live births 218 308
y: yes, n: no, dm: data missing, p: probability, SCBU: special care baby unit. Data from twin pairs was excluded.
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prevalence of MCM after exposure to LTG (5.4%, 2/37) was higher
than that after CBZ (3.0%, 2/66) but neither differed signiﬁcantly
from the control level of 2.1% (see Table 4). Babies of WWTE, who
had taken high dose folic acid pre-conception, had MCM
prevalence of 6.25% (5/80) compared with 6.29% (9/143) (OR
0.99, CI 0.32–3.07; p = 1.00) in babies, whose mothers had taken
the lower dose or none.
Individual malformations are listed with pre-conception doses
of AED and/or folic acid in Table 5. Three MCMwere detected well
after birth. The atrial septal defect (Table 5) was diagnosed and
corrected by surgery in the second year; during surgery a
diaphragmatic defect was found and repaired. The clubfoot was
detected at pre-natal scan but not diagnosed as a major
malformation until early treatments had failed and surgical
correction became necessary. Hydronephrosis in the child of a
WWE on no AED was detected at 2 years during investigation for
recurrent urinary tract infection.
The babywith spina biﬁda (Table 5, column 1) had hypospadias
and radial ray defects in addition to a sacral meningomyelocele.
Four babies with MCM (3 WWTE, 1 control) had chromosome
abnormalities and were not included in the comparisons of
outcome between different AED.
In the WWTE 6 of 17 MCM were identiﬁed on ultrasound scan
before birth (see Table 5). Four of thesewere routine and twowere
extra scans. Only 1 in 8 of the cardiovascularMCMwas detected by
ultrasound. In the control women 3 of 7 MCM were detected by
routine scans. One pregnancy only in the WWTE was terminated.
This was because of intense maternal anxiety about possibleTable 4
Prevalence of major congenital malformations in babies of womenwith treated epilepsy
(WWUTE) on no AED, compared with controls.
Treatment Major malformations
y n dm total
Controls 6 279 30 315
WWTE 14 198 19 231
AED
None 1 40 5 46
Monotherapy 10 159 16 185
Polytherapy 4 39 3 46
Mono
CBZ 2 64 8 74
VPA 6 47 4 57
LTG 2 35 3 40
Otherb 0 13 1 14
Poly
No VPA 0 19 1 20
With VPA 4 20 2 26
All AED
No VPA 4 131 13 148
With VPA 10 67 6 83
a Fisher’s exact test.
b Other monotherapies, gabapentin 2, oxazepam 1, phenytoin 7, topiramate 3, vigaba
with chromosome abnormality), %=100y/(y +n), CBZ carbamazepine, LTG lamotrigine,adverse effects of exposure to VPA. The mother’s decision was not
based on the result of a scan.
In the search for features that discriminate for MCM, 21
variables were considered. These included maternal age, multi-
parity, gestational age at recruitment, family history of MCM,
employment, complicated pregnancy, convulsive seizures, AED
(CBZ, VPA or LTG), treatment change, high dose folate pre-
conception, alcohol and smoking.
Stepwise discriminant analysis, applied to the total subject
population (WWE and controls), identiﬁed a solution set of
signiﬁcant discriminators in order of decreasing importance with
respect to MCM; these were treatment with VPA (standardised
discriminant coefﬁcient (SDC) = 0.69), complicated pregnancy
(SDC = 0.60), convulsive seizures (SDC = 0.43), multi-parity
(SDC = 0.42). These were included in the solution set of dis-
criminators by an F to enter 3.84. All other variables had an F to
enter of less than 3.84 and were thus excluded from the solution
set. Gestational age at recruitment was not a signiﬁcant
discriminator and when entered into a single step discriminant
equation with the solution set variables, its SDC was 0.04
compared to 0.69 for VPA. The values of SDC quoted above were
obtained from the discriminant function using the solution set of
variables and gestational age. The discriminant function using only
the solution set variables gave slightly larger values to the SDC, for
example, VPA (SDC = 0.70).
Five pregnancies in WWTE (5/226 = 2.2%) ended in death, one
by termination (referred to above), two by stillbirth, one by
cot death in the ﬁrst week and one from heart failure during the
ﬁrst year. In two cases the in utero exposure was to VPA and in(WWTE) on different antiepileptic drugs (AED), and womenwith untreated epilepsy
Odds ratio Conﬁdence interval p
% OR 95% CI
2.1 –
6.6 3.29 1.24–8.70 0.02
2.4 1.16 1.00a
5.9 2.92 1.04–8.20 0.06
9.3 4.77 1.29–17.65 0.03
3.0 1.45 0.23–7.37 0.65
11.3 5.94 1.84–19.19 0.01
5.4 2.66 0.52–13.68 0.23
0.0 –
0.0 –
16.7 9.30 2.43–35.66 0.004
3.0 1.42 0.39–5.12 0.73
13.0 6.94 2.44–16.20 0.001
trin 1; y: yes, n: no, dm: data missing (including major malformation in association
VPA sodium valproate.
Table 5
Major congenital malformations, pre-conceptual antiepileptic drug (AED) and folate doses, in babies of women with treated epilepsy (WWTE) and of controls.
Babies of WWTE Babies of control women
Malformation AED1 (mg) AED2 (mg) Folate (mg) Malformation Folate (mg)
Spina biﬁdaa,b VPA 2000 VGT 2000 Spina biﬁda
Cerebellar defecta LTG 150 Pulmonary cysta
Coarctation of aortac VPA 1200 Polycystic kidneya 0.4
Coarctation of aorta VPA 1000 Hydronephrosis
Atrial septal defectc VPA 700 5.0 Hypospadias
Ventricular septal def. VPA 1000 5.0 Hip dysplasia
Ventricular septal def.a VPA 600 PHT 350
Ventricular septal def. VPA 2000 LTG 50 0.4
Cleft lip and palatea CBZ 600
Hydronephrosisa,c VPA 900
Hypospadiasc CBZ 400
extra digit VPA 1000 5.0
Radial ray defect VPA 600 LTG 400 5.0
Club foota LTG 100
With chromosome def.
Atrial septal defectd – Brain cysta,e
Fallot’s tetralogyf CBZ 100 5.0
Parathyroid agenesisf LEV 2000 TPM 150
a Detected by ultrasound.
b Child also had hypospadias and radial ray defect.
c Reported previously in multi-centre NEAD study.6
d Downs.
e Edwards.
f Di George syndrome; CBZ carbamazepine, LTG lamotrigine, LEV levetiracetam, PHT phenytoin, TPM topiramate, VPA valproate, VGT vigabatrin.
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310 = 0.3%; p = 0.09, Fisher’s exact test). In the untreated
epilepsy group there was one late miscarriage giving 6 deaths
in the offspring of WWE as a whole (6/272 = 2.2%, p = 0.05).
There were 2 maternal deaths during the early infancy of the
child, one seizure-related amongst WWE and one road trafﬁc
accident amongst controls.
4. Discussion
All the women recruited into this study had already begun to
attend NHS clinics for their antenatal care. The WWE were not
under the care of the investigators but were identiﬁed by NHS
midwives in their routinework. They introduced them to the study
and invited them to meet the research nurses. This inclusive
approach is believed to have yielded a broad population of
pregnant WWE that does not exclude those with less organised
lives, who have failed to access specialist epilepsy services. The
proportion of 2.7WWE recruited per thousand recorded birthswas
less than the widely accepted population prevalence of 3–5 WWE
per thousand pregnancies.23 Nevertheless the proportion recruited
was considered large enough to be representative of the whole.
The broad spread of gestational age at recruitment does
however mean that a variable amount of information about the
pregnancy was obtained by retrospection. Equally the later
recruitment of women controls means that differences due to
gestational age at recruitment could be confounded with
differences due to treated epilepsy.
It is possible that some pregnant women, who were potential
subjects for this study, had terminations for fetal abnormalities
found on ultrasound scan (19–21 weeks) and were therefore no
longer available for recruitment. This would lead to underestima-
tion of major congenital malformations (MCM) in WWE but more
particularly in controls, since the proportion of women recruited
after 20 weeks was greater in the control group.
The incidence of termination of pregnancy for fetal malforma-
tion in pregnant women without epilepsy has been reported as
0.16% (3 terminations in 2206 pregnancies20). It is unlikelytherefore that any women had been removed by earlier termina-
tion from the group of 214 control subjects recruited after 20
weeks gestation in this study. The possibility cannot be excluded
however.
There were no known terminations for malformation in this
study even in the nine cases (Table 5, footnote ‘a’) where MCM
were detected by pre-natal ultrasound. All the MCM amongst
controls were found in women who had entered the study after 20
weeks. The observed prevalence of MCM in the offspring of
controls (2.1%, Table 4) accords well with the incidence of births
with congenital malformations in healthy women obtained by
meta-analysis of 16 published studies (2.28%; CI 1.46–3.10).20 The
authors are therefore satisﬁed that underestimation of MCM in
control pregnancies is unlikely to have occurred.
The distribution of epilepsy syndromes in this study (see Table
1) was very similar to that found by Gaily et al.24 Half the WWE
(52%) had no seizures during the pregnancy. This is consistentwith
recent studies, which give the proportion of WWE seizure-free
throughout pregnancy as 30–80%.2–7 Seizure-related trauma was
uncommon and there was no evidence of resulting harm to the
fetus.
Most WWE (66.5%) received one AED only. Whilst broadly in
line with accepted guidelines25,26 this is lower than the mono-
therapy rate (70–90%) reported in recent studies.7,16,27 The main
drugs taken, CBZ, VPA and LTG, match those reported by the UK
Epilepsy and Pregnancy Register.16 The large number ofWWEwith
changes in AED treatment during pregnancy (35%)was unexpected
and no one cause is known. It is suspected that in some cases AED
doses were reduced before conception and increased during
pregnancy when seizures recurred. Avoidance, if possible, of VPA
doses above 1000 mg/day has been recommended.25 Fourteen
WWE on VPA monotherapy received doses above 1000 mg/day.
Four of thesewomen had no tonic clonic seizures during pregnancy
and may therefore have been suitable for dose reduction before
conception.
It was expected that the WWUTE (17%), who remained largely
seizure-free, would have the same outcome to pregnancy as the
control group. This has proved to be so. There were no signiﬁcant
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delivery, gestational age and weight at birth or prevalence of
MCM. To avoid bias towards a good outcome the results from the
women with treated epilepsy (WWTE) have been presented
separately.
In obstetric terms the similarities betweenWWTE and controls
were more impressive than the differences. Pregnancy without
complication culminating in a normal vaginal delivery was the
most common sequence in each. There was however a signiﬁcant
increase in pregnancies with complications in WWTE compared
with controls. This was attributable mainly to the increase in
vaginal bleeding. This increase failed to attain signiﬁcance after
correction for multiple tests but it has also been found in other
studies.9,10 We have not found the reported increases in urinary
infection,10 hypertension,9,11 breech presentation,8 caesarean
section2,8 or pre-term delivery.4,9,10 We found no increase in
babies that were unusually small.2,7,28
The impressive differences between WWTE and controls
related to the serious adverse outcomes of MCM and death. The
6.6% prevalence of MCM amongst all recorded live births inWWTE
(Table 4) was consistent with the 7.1% (CI 5.6–8.5) obtained by
meta-analysis of 79 published studies.20 The level of agreement
suggests that underestimation of MCM arising from the extension
of recruitment beyond 20 weeks gestation is unlikely. There were
no terminations for MCM. The strongest discriminator for MCM
was exposure to VPA. This is consistent with other reports.6,13–17,29
The mortality amongst the offspring of WWTE was also higher but
there was no particular association between a fatal outcome and
exposure to VPA. Increased perinatal mortality has been reported
previously.18
Cardiovascular MCMs were relatively frequent in the babies
of WWTE but the proportion detected by pre-natal ultrasound
was low. There may be a case for an extra scan in WWTE at a
later stage of gestation, when the heart can be visualised in more
detail.
A third ofWWTE took high dose folic acid before conception but
this was not associated with a lower prevalence of MCM. This is
consistent with results from the UK Epilepsy and Pregnancy
Register.30 Folic acid supplementation, mainly at high dose, did
however reduce spontaneous miscarriage in WWE receiving
VPA.31
There have been few controlled studies with the newer AEDs in
pregnancy. The outcome in WWTE on LTG monotherapy was
therefore of particular interest. The prevalence of MCM did not
differ signiﬁcantly from the level in controls (Table 4) but
conﬁdence in this observation is limited by the modest group size.
The number of WWTE taking LTG was less than planned but the
observed prevalence of MCM corresponded with that reported for
doses above 200 mg/day by the UK Epilepsy and Pregnancy
Register.16
Our results have implications for pre-conceptual counselling. In
patients with focal epilepsy CBZ and VPA have comparable
efﬁcacy.32 The available evidence would encourage a woman
receiving VPA for focal epilepsy to change to CBZ before
conception. The choice for a woman with IGE is less clear. Both
VPA and LTG are effective against IGE33 although VPA provedmore
efﬁcacious than LTG in a recent randomised controlled trial34 and
other studies have shown LTG to be less effective particularly
against absence and myoclonic seizures.33,35,36 Leaving aside
newer AEDs, with which there is not yet sufﬁcient pregnancy
experience, shemight choose to stay on VPA at a reduced dose or to
change to LTG. Either of these changes could allow seizures to
recur.
The authors recognise the need for prospective studies of
sufﬁcient size, and with a matched control group, that focus not
only on the immediate outcome of pregnancy but also on thedevelopment of the child in the longer term. Our retrospective
studies have suggested that cognitive development can be
impaired.37,38 This paper relates to the ﬁrst phase of a prospective
study in which the later development of the children is being
monitored into the school years and will be reported on in
subsequent papers.
5. Conclusions
Amongst the women with epilepsy a third had convulsive
seizures but these did not increase as pregnancy advanced.
Overnight stay in hospital was uncommon and physical injury was
rare. Pregnancieswith complicationsweremore commonbutmost
women had a normal delivery.
Major congenital malformations were increased, particularly
when the fetus had been exposed to valproate. Fetal/infant deaths
were increased. They were not particularly associated with
exposure to any one antiepileptic drug.
Statistical analysis
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